IBL HealthCare reports FY26 PAT of PKR 220.4m (EPS Rs 2.24), up 5.8% YoY; operating cash flow reaches PKR 659.2m.
Executive Summary
IBL HealthCare Limited has announced its financial results for the full year ended June 30, 2026 (FY26). The company posted a revenue growth of 6.58% YoY and a gross profit improvement of 13.67% YoY. Profit after taxation rose 5.77% YoY to PKR 220.40 million (EPS Rs. 2.24) compared to PKR 208.37 million (restated EPS Rs. 2.11) in FY25. The Board did not recommend any cash dividend or bonus shares for the year.
Key Highlights
- Payout / Dividend: Nil (No cash dividend, bonus shares, or rights declared).
- Margin Expansion: Gross profit margin expanded to 35.70% in FY26 from 33.48% in FY25 due to efficient cost of sales control.
- Finance Cost Savings: Finance costs dropped by 28.81% YoY to PKR 42.87 million, supported by reduced debt levels.
- Substantial Debt Reduction: Short-term borrowings decreased sharply by 95.07% to PKR 6.73 million from PKR 136.36 million.
- Cash Flow Turnaround: Operating cash flows turned strongly positive at PKR 659.20 million versus negative PKR 259.67 million last year.
Financial Performance Comparison (PKR '000)
| Financial Metric | FY26 | FY25 | YoY Change |
|---|---|---|---|
| Revenue from Contracts | 4,607,109 | 4,322,471 | +6.58% |
| Cost of Sales | (2,962,267) | (2,875,495) | +3.02% |
| Gross Profit | 1,644,842 | 1,446,976 | +13.67% |
| Marketing & Distribution | (1,006,116) | (858,387) | +17.21% |
| Administrative Expenses | (194,284) | (144,002) | +34.92% |
| Net Impairment Loss | (11,338) | - | N/A |
| Finance Cost | (42,866) | (60,210) | -28.81% |
| Profit Before Income Tax | 401,256 | 340,212 | +17.94% |
| Income Tax Expense | (180,854) | (131,841) | +37.18% |
| Profit After Tax | 220,402 | 208,371 | +5.77% |
| EPS (Rs) | 2.24 | 2.11 | +6.16% |
Risks & Opportunities
- Selling, marketing, and admin expenses grew faster than revenue (up 17.2% and 34.9% YoY respectively).
- Taxation expense surged 37.18% YoY, capping net profit growth.
- Solid operational cash inflows (PKR 659.20m) provide operational strength and balance sheet flexibility.
- Near elimination of short-term borrowings reduces interest rate exposure significantly.
IBL HealthCare delivered steady top-line and bottom-line growth alongside significant deleveraging and a strong cash flow recovery. While the absence of a dividend payout may disappoint income-focused investors in the short term, the company's financial balance sheet structure has improved noticeably.